Association of vaccination status and vaccine type with quality of life in hospitalized COVID-19 patients
Abstract
Aims: The aim of this study is to investigate whether vaccination, as one of the most critical preventive measures against infectious diseases, has an impact on the quality of life post-infection. Additionally, it aims to evaluate the effects of different vaccine types used in the prevention of COVID-19 on post-infection quality of life.
Methods: This single-center observational study included adults hospitalized with COVID-19 who were evaluated at a follow-up center one month after discharge. Participants were assessed at two visits one month apart. Quality of life was evaluated using the SF-12 Quality of Life Scale, and findings were compared according to vaccination status and vaccine type.
Results: The study was completed with 98 participants aged 28–87 years, with a mean age of 56±13.0 years. While physical health scores did not differ significantly between the two follow-ups in the unvaccinated group, a significant improvement was observed among vaccinated participants (p=0.027). Among the vaccinated group, physical health scores showed no significant difference between the two follow-ups for mRNA vaccine recipients, but a significant improvement was observed for those who had received inactivated vaccines (p=0.015). The number of complaints decreased significantly in both vaccine groups. Positive correlations were found between the values of the SF-12 scale across the two follow-ups (p<0.05). Conversely, negative correlations were observed between SF-12 scores and the number of complaints at both follow-ups (p<0.001). A positive correlation was also noted between the number of complaints across the two follow-ups (p<0.001).
Conclusion: Vaccination was associated with improvement in some quality-of-life parameters during follow-up after hospitalization for COVID-19. Differences between vaccine types should be interpreted cautiously and confirmed in larger studies.
Keywords
Supporting Institution
Ethical Statement
Thanks
References
- Fernández-de-las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Cuadrado ML, Florencio LL. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int J Environ Res Public Health. 2021;18(5):2621. doi:10.3390/ijerph18052621.
- Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi:10.1136/bmj.n136.
- Corum J, Grady D, Wee SL, Zimmer C. Coronavirus vaccine tracker. The New York Times. Published 2020. Accessed December 12, 2025. https://www.nytimes.com/interactive/-2020/science/coronavirus-vaccine-tracker.html
- Gürbüz S, Aydın S, Çöl M. COVID-19 aşı çalışmaları ve uygulamaları. In: Yeni Koronavirüs Pandemisi Sürecinde Türkiye’de COVID-19 Aşılaması ve Bağışıklama Hizmetlerinin Durumu. Türk Tabipleri Birliği; 2021:45-60.
- Yavuz E. COVID-19 aşıları. Turk J Fam Pract. 2020;24(4):227-234.
- Glatman-Freedman A, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, Bromberg M. Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 Delta variant infection, Israel, 2021. Emerg Infect Dis. 2021;27(11):2919-2922. doi:10.3201/eid2711.211886.
- Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922-1924. doi:10.15585/mmwr.mm6950e2.
- O’Sullivan O, Barker-Davies RM, Thompson K, et al. Rehabilitation post-COVID-19: cross-sectional observations using the Stanford Hall remote assessment tool. BMJ Mil Health. 2023;169(3):243-248. doi:10.1136/bmjmilitary-2021-001856.
Details
Primary Language
English
Subjects
Infectious Diseases
Journal Section
Research Article
Authors
Publication Date
September 27, 2026
Submission Date
January 19, 2026
Acceptance Date
June 18, 2026
Published in Issue
Year 2026 Volume: 6 Number: 3